Francisco Trust Under Agreemen Sells 25,281 Shares of Dyadic International (NASDAQ:DYAI) Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 25,281 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $1.87, for a total transaction of $47,275.47. Following the sale, the insider owned 3,496,907 shares in the company, valued at $6,539,216.09. The trade was a 0.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Dyadic International Stock Up 9.5%

Dyadic International stock opened at $1.06 on Wednesday. The firm has a 50 day simple moving average of $0.78 and a 200 day simple moving average of $0.83. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 4.08. Dyadic International Inc. has a 1-year low of $0.65 and a 1-year high of $1.35. The firm has a market capitalization of $38.63 million, a price-to-earnings ratio of -4.61 and a beta of 1.15.

Dyadic International (NASDAQ:DYAI) last posted its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.The company had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. On average, analysts predict that Dyadic International Inc. will post 0.13 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Bank of America Corp DE raised its position in shares of Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares in the last quarter. Marathon Capital Management purchased a new position in Dyadic International during the third quarter worth about $41,000. Geode Capital Management LLC grew its position in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares in the last quarter. Landscape Capital Management L.L.C. bought a new position in Dyadic International in the 3rd quarter worth about $190,000. Finally, Apis Capital Advisors LLC bought a new position in Dyadic International in the 3rd quarter worth about $1,817,000. Institutional investors own 27.95% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $3.00.

Dyadic International News Roundup

Here are the key news stories impacting Dyadic International this week:

• Positive Sentiment: Dyadic said global collaborations are continuing to validate its C1 platform and expand commercial potential, including work tied to Ebola preparedness, which may improve the long-term outlook for its technology. Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
• Neutral Sentiment: Recent quarterly results were mixed: revenue came in above expectations, but EPS missed estimates, keeping attention on whether Dyadic can convert its technology into sustained profitability.
• Negative Sentiment: Major shareholder Francisco Trust Under Agreement disclosed multiple recent stock sales, which may pressure sentiment because insider selling can raise concerns about near-term confidence in the shares.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.